Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Kristin Cadenhead

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentPsychiatry
    Address9500 Gilman Drive #0810
    CA La Jolla 92093
    Phone619-543-6445
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview

      Biography

      Dr. Kristin Cadenhead a Professor of Psychiatry at University of California San Diego and an attending physician at both the Veterans Administration and the UCSD Medical Centers. She serves as an Associate Residency Training Director for the Department of Psychiatry and a Clinical Foundations Director for the School of Medicine. She is the Director of the Cognitive Assessment and Risk Evaluation (CARE) Program, a research and clinical program that focuses on early identification, intervention and prevention of serious mental illness. Dr. Cadenhead is the Medical Director of the Mental Health Primary Care clinic at the VA Medical Center. She received her BA degree in Biology/Psychology from Rice University in Houston, Texas. She then earned her medical degree from the University of Texas Medical Branch in Galveston. She completed her residency in Psychiatry and Fellowship in Schizophrenia research at UCSD.

      Research Interests

      Primary research interests include vulnerability markers in the schizophrenia spectrum of disorders (prodromal schizophrenia and schizotypal personality disorder) and the genetics of schizophrenia. Dr. Cadenhead is the Director of the “CARE” (Cognitive Assessment and Risk Evaluation) Program to study the early signs of psychosis in adolescents and young adults. Funded by the National Institutes of Health, the CARE program provides education and community outreach to the National Alliance for the Mentally Ill, the San Diego Public Schools and other community health and physician organizations. The study is longitudinal and assesses clinical as well as physiologic and cognitive factors that may be predictive of developing schizophrenia. A major aim of the CARE program is to identify psychosis early so that it is possible to intervene earlier and perhaps prevent some of the devastating effects of schizophrenia. Dr. Cadenhead is also interested in the heritability of the information processing traits and participates in ongoing studies in normal twins. Dr. Cadenhead has expertise in the treatment of psychotic disorders and provides regular consultations.

      Clinical Focus

      The CARE Program provides clinical care to individuals who are developing the initial signs of a psychotic illness. The treatment philosophy includes a multidisciplinary approach with pharmacologic management, social services, stress management and psychoeducation as part of the program. Dr. Cadenhead is also the Director of the Psychiatry Primary Care Clinic at the SDVAMC. The Primary Care Clinic is staffed by psychiatry residents who provide both psychiatric and primary care to psychiatric patients while they are supervised by Attending Physicians in Psychiatry and Internal Medicine.


      Collapse Research 
      Collapse Research Activities and Funding
      3/3-Cognitive Behavioral Social Skills Training for Youth at Risk of Psychosis
      NIH/NIMH R01MH105243Sep 26, 2014 - Jul 31, 2019
      Role: Principal Investigator
      Compensatory Cognitive Training in Clinical High Risk Latino Youth
      NIH/NIMH R34MH105247Sep 12, 2014 - Jun 30, 2018
      Role: Principal Investigator
      Inflammatory Biomarkers in First Episode Psychosis: A Mexico/US Collaboration
      NIH/NIMH R21MH102374May 1, 2014 - Apr 30, 2016
      Role: Principal Investigator
      6/9-Predictors and Mechanisms of Conversion to Psychosis
      NIH/NIMH U01MH081944Dec 1, 2007 - Jun 30, 2019
      Role: Principal Investigator
      Vulnerability Markers in the Prodrome and First Episode of Schizophrenia
      NIH/NIMH K24MH076191Sep 29, 2007 - Jun 30, 2013
      Role: Principal Investigator
      Vulnerability Markers in Prodromal Schizophrenia
      NIH/NIMH R01MH060720Dec 1, 1999 - Apr 30, 2012
      Role: Principal Investigator
      INFORMATION PROCESSING DEFICITS IN SCHIZOTYPAL PATIENTS
      NIH/NIMH K20MH001124Apr 1, 1995 - Mar 31, 2001
      Role: Principal Investigator
      THE SCHIZOPHRENIC SPECTRUM AND INFORMATION PROCESSING
      NIH/NIMH F32MH010072Jul 28, 1991
      Role: Principal Investigator

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Lu Y, Marshall C, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon D, Addington J. Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety. Psychiatry Res. 2017 Aug 31. PMID: 28886901.
        View in: PubMed
      2. Georgopoulos G, Stowkowy J, Liu L, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. The role of a family history of psychosis for youth at clinical high risk of psychosis. Early Interv Psychiatry. 2017 Aug 09. PMID: 28792113.
        View in: PubMed
      3. Marshall C, Lu Y, Lyngberg K, Deighton S, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon D, Addington J. Changes in symptom content from a clinical high-risk state to conversion to psychosis. Early Interv Psychiatry. 2017 Aug 03. PMID: 28771938.
        View in: PubMed
      4. Kline ER, Seidman LJ, Cornblatt BA, Woodberry KA, Bryant C, Bearden CE, Cadenhead K, Cannon TD, Mathalon DH, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Addington J. Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophr Res. 2017 Jun 01. PMID: 28578922.
        View in: PubMed
      5. Minichino A, Ando' A, Francesconi M, Salatino A, Delle Chiaie R, Cadenhead K. Investigating the link between drug-naive first episode psychoses (FEPs), weight gain abnormalities and brain structural damages: Relevance and implications for therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jul 03; 77:9-22. PMID: 28363765.
        View in: PubMed
      6. Chung Y, Haut KM, He G, van Erp TG, McEwen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, Woods SW, Cannon TD. Ventricular enlargement and progressive reduction of cortical gray matter are linked in prodromal youth who develop psychosis. Schizophr Res. 2017 Feb 25. PMID: 28245961.
        View in: PubMed
      7. Minichino A, Francesconi M, Carrión RE, Bevilacqua A, Parisi M, Rullo S, Ando' A, Biondi M, Delle Chiaie R, Cadenhead K. Prediction of functional outcome in young patients with a recent-onset psychiatric disorder: Beyond the traditional diagnostic classification system. Schizophr Res. 2016 Dec 29. PMID: 28041918.
        View in: PubMed
      8. Seidman LJ, Shapiro DI, Stone WS, Woodberry KA, Ronzio A, Cornblatt BA, Addington J, Bearden CE, Cadenhead K, Cannon TD, Mathalon DH, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW. Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study. JAMA Psychiatry. 2016 Nov 2. PMID: 27806157.
        View in: PubMed
      9. Francesconi M, Minichino A, Carrión RE, Chiaie RD, Bevilacqua A, Parisi M, Rullo S, Bersani FS, Biondi M, Cadenhead K. Theory of Mind as a mediator variable between neurocognition and functioning in young individuals in treatment with secondary services for non-psychotic disorders. Psychiatry Res. 2016 Oct 6; 246:415-420. PMID: 27788462.
        View in: PubMed
      10. Cannon TD, Yu C, Addington J, Bearden CE, Cadenhead K, Cornblatt BA, Heinssen R, Jeffries CD, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Kattan MW. An Individualized Risk Calculator for Research in Prodromal Psychosis. Am J Psychiatry. 2016 Oct 1; 173(10):980-988. PMID: 27363508.
        View in: PubMed
      11. Buchy L, Mathalon DH, Cannon TD, Cadenhead K, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Addington J. Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. Psychiatry Res. 2016 Aug 30; 254:3-9. PMID: 27289213.
        View in: PubMed
      12. Deighton S, Buchy L, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon D, Addington J. Traumatic brain injury in individuals at clinical high risk for psychosis. Schizophr Res. 2016 Jul; 174(1-3):77-81. PMID: 27165121.
        View in: PubMed
      13. Marshall C, Deighton S, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon D, Addington J. The Violent Content in Attenuated Psychotic Symptoms. Psychiatry Res. 2016 Aug 30; 242:61-6. PMID: 27259137.
        View in: PubMed
      14. Millard SP, Shofer J, Braff D, Calkins M, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur R, Gur R, Lazzeroni LC, Light GA, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone WS, Sprock J, Sugar CA, Swerdlow NR, Tsuang M, Turetsky B, Radant A, Tsuang DW. Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. Schizophr Res. 2016 Jul; 174(1-3):1-9. PMID: 27132484.
        View in: PubMed
      15. McLaughlin D, Carrión RE, Auther AM, Olvet DM, Addington J, Bearden CE, Cadenhead K, Cannon TD, Heinssen RK, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Goldberg TE, Harvey PD, Cornblatt BA. Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. Schizophr Bull. 2016 Sep; 42(5):1234-42. PMID: 27105902.
        View in: PubMed
      16. Cadenhead K, Mirzakhanian H. A Case of Attenuated Psychosis Syndrome: A Broad Differential Diagnosis Requires Broad-Spectrum Treatment. Am J Psychiatry. 2016 Apr 1; 173(4):321-9. PMID: 27035531.
        View in: PubMed
      17. Moskow DM, Addington J, Bearden CE, Cadenhead K, Cornblatt BA, Heinssen R, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Cannon TD, Woods SW, Walker EF. The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis. Schizophr Res. 2016 Apr; 172(1-3):29-34. PMID: 26905038.
        View in: PubMed
      18. Stone WS, Mesholam-Gately RI, Giuliano AJ, Woodberry KA, Addington J, Bearden CE, Cadenhead K, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, McCarley RW, Heinssen R, Green MF, Nuechterlein K, Seidman LJ. Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. Schizophr Res. 2016 Apr; 172(1-3):106-13. PMID: 26896388.
        View in: PubMed
      19. Stowkowy J, Liu L, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. Early traumatic experiences, perceived discrimination and conversion to psychosis in those at clinical high risk for psychosis. Soc Psychiatry Psychiatr Epidemiol. 2016 Apr; 51(4):497-503. PMID: 26851943.
        View in: PubMed
      20. Minichino A, Singh F, Pineda J, Friederich E, Cadenhead K. Biological Motion induced mu suppression is reduced in Early Psychosis (EP) patients with active negative symptoms and Autism Spectrum Disorders (ASD). Psychiatry Res. 2016 Apr 30; 238:374-7. PMID: 26970656.
        View in: PubMed
      21. Piskulic D, Liu L, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. Social cognition over time in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. Schizophr Res. 2016 Mar; 171(1-3):176-81. PMID: 26785807.
        View in: PubMed
      22. Singh F, Nunag J, Muldoon G, Cadenhead K, Pineda JA, Feifel D. Effects of intranasal oxytocin on neural processing within a socially relevant neural circuit. Eur Neuropsychopharmacol. 2016 Mar; 26(3):626-30. PMID: 26727038.
        View in: PubMed
      23. Buchy L, Seidman LJ, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Stone W, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. Psychiatry Res. 2015 Dec 30; 230(3):878-84. PMID: 26626949.
        View in: PubMed
      24. Buchy L, Cannon TD, Anticevic A, Lyngberg K, Cadenhead K, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. BMC Psychiatry. 2015; 15:276. PMID: 26553191; PMCID: PMC4640353.
      25. McAusland L, Buchy L, Cadenhead K, Cannon TD, Cornblatt BA, Heinssen R, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. Anxiety in youth at clinical high risk for psychosis. Early Interv Psychiatry. 2015 Oct 12. PMID: 26456932.
        View in: PubMed
      26. Perkins DO, Jeffries CD, Cornblatt BA, Woods SW, Addington J, Bearden CE, Cadenhead K, Cannon TD, Heinssen R, Mathalon DH, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Severity of thought disorder predicts psychosis in persons at clinical high-risk. Schizophr Res. 2015 Dec; 169(1-3):169-77. PMID: 26441004.
        View in: PubMed
      27. Webb JR, Addington J, Perkins DO, Bearden CE, Cadenhead K, Cannon TD, Cornblatt BA, Heinssen RK, Seidman LJ, Tarbox SI, Tsuang MT, Walker EF, McGlashan TH, Woods SW. Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. Schizophr Bull. 2015 Sep; 41(5):1066-75. PMID: 26272875.
        View in: PubMed
      28. Anticevic A, Haut K, Murray JD, Repovs G, Yang GJ, Diehl C, McEwen SC, Bearden CE, Addington J, Goodyear B, Cadenhead K, Mirzakhanian H, Cornblatt BA, Olvet D, Mathalon DH, McGlashan TH, Perkins DO, Belger A, Seidman LJ, Tsuang MT, van Erp TG, Walker EF, Hamann S, Woods SW, Qiu M, Cannon TD. Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. JAMA Psychiatry. 2015 Sep 1; 72(9):882-91. PMID: 26267151.
        View in: PubMed
      29. Waford RN, MacDonald A, Goines K, Novacek DM, Trotman HD, Elaine F W, Addington J, Bearden CE, Cadenhead K, Cannon TD, Cornblatt BA, Heinssen R, Mathalon DH, Tsuang MT, Perkins DO, Seidman LJ, Woods SW, McGlashan TH. Demographic correlates of attenuated positive psychotic symptoms. Schizophr Res. 2015 Aug; 166(1-3):31-6. PMID: 25999040.
        View in: PubMed
      30. Barbato M, Liu L, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Heinssen R, Addington J. Theory of Mind, Emotion Recognition and Social Perception in Individuals at Clinical High Risk for Psychosis: findings from the NAPLS-2 cohort. Schizophr Res Cogn. 2015 Sep; 2(3):133-139. PMID: 27695675.
        View in: PubMed
      31. Addington J, Liu L, Buchy L, Cadenhead K, Cannon TD, Cornblatt BA, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, McGlashan TH. North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. J Nerv Ment Dis. 2015 May; 203(5):328-35. PMID: 25919383.
        View in: PubMed
      32. Stowkowy J, Liu L, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Heinssen R, Addington J. Core Schemas in Youth at Clinical High Risk for Psychosis. Behav Cogn Psychother. 2016 Mar; 44(2):203-13. PMID: 25896713.
        View in: PubMed
      33. Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead K, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res. 2015 Apr; 163(1-3):73-9. PMID: 25682549.
        View in: PubMed
      34. Trotman HD, Holtzman CW, Walker EF, Addington JM, Bearden CE, Cadenhead K, Cannon TD, Cornblatt BA, Heinssen RK, Mathalon DH, Tsuang MT, Perkins DO, Seidman LJ, Woods SW, McGlashan TH. Stress exposure and sensitivity in the clinical high-risk syndrome: Initial findings from the North American Prodrome Longitudinal Study (NAPLS). Schizophr Res. 2014 Dec; 160(1-3):104-9. PMID: 25443665.
        View in: PubMed
      35. Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead K, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R. Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project. Schizophr Bull. 2015 Mar; 41(2):419-28. PMID: 25103207.
        View in: PubMed
      36. Solís-Vivanco R, Mondragón-Maya A, León-Ortiz P, Rodríguez-Agudelo Y, Cadenhead K, de la Fuente-Sandoval C. Mismatch Negativity reduction in the left cortical regions in first-episode psychosis and in individuals at ultra high-risk for psychosis. Schizophr Res. 2014 Sep; 158(1-3):58-63. PMID: 25064664.
        View in: PubMed
      37. Woods SW, Walsh BC, Addington J, Cadenhead K, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tarbox SI, Tsuang MT, Walker EF, McGlashan TH. Current status specifiers for patients at clinical high risk for psychosis. Schizophr Res. 2014 Sep; 158(1-3):69-75. PMID: 25012147.
        View in: PubMed
      38. Marshall C, Denny E, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Walker E, Addington J. The content of attenuated psychotic symptoms in those at clinical high risk for psychosis. Psychiatry Res. 2014 Nov 30; 219(3):506-12. PMID: 25048759.
        View in: PubMed
      39. Cannon TD, Chung Y, He G, Sun D, Jacobson A, van Erp TG, McEwen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Jeffries C, Seidman LJ, Tsuang M, Walker E, Woods SW, Heinssen R. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2015 Jan 15; 77(2):147-57. PMID: 25034946.
        View in: PubMed
      40. Schmeidler J, Lazzeroni LC, Swerdlow NR, Ferreira RP, Braff DL, Calkins ME, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Stone WS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Res. 2014 Sep 30; 219(1):67-71. PMID: 24913833.
        View in: PubMed
      41. Forsyth JK, McEwen SC, Gee DG, Bearden CE, Addington J, Goodyear B, Cadenhead K, Mirzakhanian H, Cornblatt BA, Olvet DM, Mathalon DH, McGlashan TH, Perkins DO, Belger A, Seidman LJ, Thermenos HW, Tsuang MT, van Erp TG, Walker EF, Hamann S, Woods SW, Qiu M, Cannon TD. Reliability of functional magnetic resonance imaging activation during working memory in a multi-site study: Analysis from the North American Prodrome Longitudinal Study. Neuroimage. 2014 Aug 15; 97:41-52. PMID: 24736173.
        View in: PubMed
      42. Alderman T, Addington J, Bearden C, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Cadenhead K. Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium. Early Interv Psychiatry. 2015 Dec; 9(6):467-75. PMID: 24576057.
        View in: PubMed
      43. Meyer EC, Carrión RE, Cornblatt BA, Addington J, Cadenhead K, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Heinssen R, Seidman LJ. The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the north american prodrome longitudinal study. Schizophr Bull. 2014 Nov; 40(6):1452-61. PMID: 24550526.
        View in: PubMed
      44. Tsuang D, Esterberg M, Braff D, Calkins M, Cadenhead K, Dobie D, Freedman R, Green MF, Greenwood T, Gur R, Gur R, Horan W, Lazzeroni LC, Light GA, Millard SP, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone W, Sprock J, Sugar C, Swerdlow N, Tsuang M, Turetsky B, Radant A. Is There an Association between Advanced Paternal Age and Endophenotype Deficit Levels in Schizophrenia? PLoS One. 2014; 9(2):e88379. PMID: 24523888.
        View in: PubMed
      45. Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead K. Substance use in clinical high risk for psychosis: a review of the literature. Early Interv Psychiatry. 2014 May; 8(2):104-12. PMID: 24224849.
        View in: PubMed
      46. Tarbox SI, Addington J, Cadenhead K, Cannon TD, Cornblatt BA, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Heinssen R, McGlashan TH, Woods SW. Premorbid functional development and conversion to psychosis in clinical high-risk youths. Dev Psychopathol. 2013 Nov; 25(4 Pt 1):1171-86. PMID: 24229556.
        View in: PubMed
      47. Tarbox SI, Addington J, Cadenhead K, Cannon TD, Cornblatt BA, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Heinssen R, McGlashan TH, Woods SW. Functional development in clinical high risk youth: Prediction of schizophrenia versus other psychotic disorders. Psychiatry Res. 2014 Jan 30; 215(1):52-60. PMID: 24200216.
        View in: PubMed
      48. Cannon TD, Sun F, McEwen SJ, Papademetris X, He G, van Erp TG, Jacobson A, Bearden CE, Walker E, Hu X, Zhou L, Seidman LJ, Thermenos HW, Cornblatt B, Olvet DM, Perkins D, Belger A, Cadenhead K, Tsuang M, Mirzakhanian H, Addington J, Frayne R, Woods SW, McGlashan TH, Constable RT, Qiu M, Mathalon DH, Thompson P, Toga AW. Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. Hum Brain Mapp. 2014 May; 35(5):2424-34. PMID: 23982962.
        View in: PubMed
      49. Cadenhead K, Dobkins K, McGovern J, Shafer K. Schizophrenia spectrum participants have reduced visual contrast sensitivity to chromatic (red/green) and luminance (light/dark) stimuli: new insights into information processing, visual channel function, and antipsychotic effects. Front Psychol. 2013; 4:535. PMID: 23970874.
        View in: PubMed
      50. Cadenhead K, Addington J, Cannon TD, Cornblatt BA, de la Fuente-Sandoval C, Mathalon DH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Bachman P, Belger A, Carrión RE, Donkers FC, Duncan E, Johannesen J, León-Ortiz P, Light G, Mondragón A, Niznikiewicz M, Nunag J, Roach BJ, Solís-Vivanco R. Between-site reliability of startle prepulse inhibition across two early psychosis consortia. Neuroreport. 2013 Aug 7; 24(11):626-30. PMID: 23799460.
        View in: PubMed
      51. Saleem MM, Stowkowy J, Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Addington J. Perceived discrimination in those at clinical high risk for psychosis. Early Interv Psychiatry. 2014 Feb; 8(1):77-81. PMID: 23773288.
        View in: PubMed
      52. Woods SW, Addington J, Bearden CE, Cadenhead K, Cannon TD, Cornblatt BA, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. Schizophr Res. 2013 Aug; 148(1-3):99-104. PMID: 23787224.
        View in: PubMed
      53. Greenwood TA, Swerdlow NR, Gur RE, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Light GA, Braff DL. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013 May 1; 170(5):521-32. PMID: 23511790.
        View in: PubMed
      54. Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead K, Cornblatt BA, Heinssen R, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Cannon TD, McGlashan TH, Woods SW. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry. 2013 Sep 15; 74(6):410-7. PMID: 23562006.
        View in: PubMed
      55. Mondragón-Maya A, Solís-Vivanco R, León-Ortiz P, Rodríguez-Agudelo Y, Yáñez-Téllez G, Bernal-Hernández J, Cadenhead K, de la Fuente-Sandoval C. Reduced P3a amplitudes in antipsychotic naïve first-episode psychosis patients and individuals at clinical high-risk for psychosis. J Psychiatr Res. 2013 Jun; 47(6):755-61. PMID: 23507048.
        View in: PubMed
      56. Addington J, Stowkowy J, Cadenhead K, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Cannon TD. Early traumatic experiences in those at clinical high risk for psychosis. Early Interv Psychiatry. 2013 Aug; 7(3):300-5. PMID: 23343384.
        View in: PubMed
      57. Walder DJ, Holtzman CW, Addington J, Cadenhead K, Tsuang M, Cornblatt B, Cannon TD, McGlashan TH, Woods SW, Perkins DO, Seidman LJ, Heinssen R, Walker EF. Sexual dimorphisms and prediction of conversion in the NAPLS psychosis prodrome. Schizophr Res. 2013 Mar; 144(1-3):43-50. PMID: 23340377.
        View in: PubMed
      58. Addington J, Cadenhead K, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Addington JA, Cannon TD. North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophr Res. 2012 Dec; 142(1-3):77-82. PMID: 23043872.
        View in: PubMed
      59. Mirzakhanian H, Singh F, Seeber K, Shafer KM, Cadenhead K. A developmental look at the attentional system in the at risk and first episode of psychosis: age related changes in attention along the psychosis spectrum. Cogn Neuropsychiatry. 2013; 18(1-2):26-43. PMID: 22994363.
        View in: PubMed
      60. Piskulic D, Addington J, Cadenhead K, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, McGlashan TH. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res. 2012 Apr 30; 196(2-3):220-4. PMID: 22445704.
        View in: PubMed
      61. Singh F, Mirzakhanian H, Fusar-Poli P, de la Fuente-Sandoval C, Cadenhead K. Ethical implications for clinical practice and future research in "at risk" individuals. Curr Pharm Des. 2012; 18(4):606-12. PMID: 22239594.
        View in: PubMed
      62. Cornblatt BA, Carrión RE, Addington J, Seidman L, Walker EF, Cannon TD, Cadenhead K, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Heinssen R, Lencz T. Risk factors for psychosis: impaired social and role functioning. Schizophr Bull. 2012 Nov; 38(6):1247-57. PMID: 22080497.
        View in: PubMed
      63. Gee DG, Karlsgodt KH, van Erp TG, Bearden CE, Lieberman MD, Belger A, Perkins DO, Olvet DM, Cornblatt BA, Constable T, Woods SW, Addington J, Cadenhead K, McGlashan TH, Seidman LJ, Tsuang MT, Walker EF, Cannon TD. Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study. Schizophr Res. 2012 Jan; 134(1):1-9. PMID: 22056201.
        View in: PubMed
      64. Domingues I, Alderman T, Cadenhead K. Strategies for effective recruitment of individuals at risk for developing psychosis. Early Interv Psychiatry. 2011 Aug; 5(3):233-41. PMID: 21707939.
        View in: PubMed
      65. Cadenhead K. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res. 2011 Jul 30; 188(2):208-16. PMID: 21555157.
        View in: PubMed
      66. Singh F, Pineda J, Cadenhead K. Association of impaired EEG mu wave suppression, negative symptoms and social functioning in biological motion processing in first episode of psychosis. Schizophr Res. 2011 Aug; 130(1-3):182-6. PMID: 21549567.
        View in: PubMed
      67. Addington J, Cornblatt BA, Cadenhead K, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011 Aug; 168(8):800-5. PMID: 21498462.
        View in: PubMed
      68. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead K, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011 Sep; 168(9):930-46. PMID: 21498463.
        View in: PubMed
      69. Stone WS, Giuliano AJ, Tsuang MT, Braff DL, Cadenhead K, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow NR, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2011 May; 128(1-3):102-10. PMID: 21288694.
        View in: PubMed
      70. Eslami A, Jahshan C, Cadenhead K. Disorganized symptoms and executive functioning predict impaired social functioning in subjects at risk for psychosis. J Neuropsychiatry Clin Neurosci. 2011; 23(4):457-60. PMID: 22231319.
        View in: PubMed
      71. Cadenhead K, Addington J, Cannon T, Cornblatt B, McGlashan T, Perkins D, Seidman L, Tsuang M, Walker E, Woods S, Heinssen R. Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv Psychiatry. 2010 Aug; 4(3):220-6. PMID: 20712727.
        View in: PubMed
      72. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead K, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010 Jun; 67(6):578-88. PMID: 20530007.
        View in: PubMed
      73. Olincy A, Braff DL, Adler LE, Cadenhead K, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):175-82. PMID: 20382002.
        View in: PubMed
      74. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Meichle SP, Millard SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010 Sep; 47(5):846-56. PMID: 20374545.
        View in: PubMed
      75. Jahshan C, Heaton RK, Golshan S, Cadenhead K. Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology. 2010 Jan; 24(1):109-20. PMID: 20063952.
        View in: PubMed
      76. Kaur T, Cadenhead K. Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci. 2010; 4:97-121. PMID: 21312398.
        View in: PubMed
      77. Walker EF, Cornblatt BA, Addington J, Cadenhead K, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Heinssen R. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res. 2009 Nov; 115(1):50-7. PMID: 19709859.
        View in: PubMed
      78. Woods SW, Addington J, Cadenhead K, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009 Sep; 35(5):894-908. PMID: 19386578.
        View in: PubMed
      79. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead K, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008 Dec 15; 64(12):1051-9. PMID: 18701089.
        View in: PubMed
      80. Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):218-28. PMID: 18406578.
        View in: PubMed
      81. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008 Jan; 65(1):28-37. PMID: 18180426.
        View in: PubMed
      82. Greenwood TA, Braff DL, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry. 2007 Nov; 64(11):1242-50. PMID: 17984393.
        View in: PubMed
      83. Ballon JS, Dean KA, Cadenhead K. Obstetrical complications in people at risk for developing schizophrenia. Schizophr Res. 2008 Jan; 98(1-3):307-11. PMID: 17961986.
        View in: PubMed
      84. Kristensen K, Cadenhead K. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007 May 30; 151(1-2):151-4. PMID: 17383738.
        View in: PubMed
      85. Ballon JS, Kaur T, Marks II, Cadenhead K. Social functioning in young people at risk for schizophrenia. Psychiatry Res. 2007 May 30; 151(1-2):29-35. PMID: 17383739.
        View in: PubMed
      86. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2007 May; 92(1-3):237-51. PMID: 17346930.
        View in: PubMed
      87. Addington J, Cadenhead K, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Heinssen R. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull. 2007 May; 33(3):665-72. PMID: 17255119.
        View in: PubMed
      88. Swerdlow NR, Light GA, Cadenhead K, Sprock J, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 Dec; 63(12):1325-35. PMID: 17146007.
        View in: PubMed
      89. Calkins ME, Dobie DJ, Cadenhead K, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull. 2007 Jan; 33(1):33-48. PMID: 17035358.
        View in: PubMed
      90. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):320-9. PMID: 17023145.
        View in: PubMed
      91. Fu EJ, Cadenhead K. Progress in the Prospective Study of the Schizophrenia Prodrome. Curr Psychos Ther Rep. 2005 Dec 1; 3(4):169-174. PMID: 21691454.
        View in: PubMed
      92. Haroun N, Dunn L, Haroun A, Cadenhead K. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull. 2006 Jan; 32(1):166-78. PMID: 16207892.
        View in: PubMed
      93. Cadenhead K, Light GA, Shafer KM, Braff DL. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biol Psychiatry. 2005 Jun 15; 57(12):1504-9. PMID: 15953486.
        View in: PubMed
      94. Seeber K, Cadenhead K. How does studying schizotypal personality disorder inform us about the prodrome of schizophrenia? Curr Psychiatry Rep. 2005 Mar; 7(1):41-50. PMID: 15717986.
        View in: PubMed
      95. Perry W, Minassian A, Cadenhead K, Sprock J, Braff D. The use of the Ego Impairment Index across the schizophrenia spectrum. J Pers Assess. 2003 Feb; 80(1):50-7. PMID: 12584067.
        View in: PubMed
      96. Cadenhead K. Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics, and the identification of the schizophrenia prodrome. Psychiatr Clin North Am. 2002 Dec; 25(4):837-53. PMID: 12462863.
        View in: PubMed
      97. Cadenhead K, Light GA, Geyer MA, McDowell JE, Braff DL. Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry. 2002 May; 159(5):869-71. PMID: 11986147.
        View in: PubMed
      98. Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA, Cadenhead K, Auerbach PP. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl). 2002 May; 161(2):189-201. PMID: 11981599.
        View in: PubMed
      99. Cadenhead K, Braff DL. Endophenotyping schizotypy: a prelude to genetic studies within the schizophrenia spectrum. Schizophr Res. 2002 Mar 1; 54(1-2):47-57. PMID: 11853978.
        View in: PubMed
      100. Granholm E, Cadenhead K, Shafer KM, Filoteo JV. Lateralized perceptual organization deficits on the global-local task in schizotypal personality disorder. J Abnorm Psychol. 2002 Feb; 111(1):42-52. PMID: 11866178.
        View in: PubMed
      101. Cadenhead K, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry. 2000 Oct; 157(10):1660-8. PMID: 11007721.
        View in: PubMed
      102. Cadenhead K, Light GA, Geyer MA, Braff DL. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am J Psychiatry. 2000 Jan; 157(1):55-9. PMID: 10618013.
        View in: PubMed
      103. Cadenhead K, Perry W, Shafer K, Braff DL. Cognitive functions in schizotypal personality disorder. Schizophr Res. 1999 May 25; 37(2):123-32. PMID: 10374648.
        View in: PubMed